- BIO-key International (BKYI, Financial) has regained compliance with Nasdaq listing requirements.
- The company resolved its non-compliance issue by filing its overdue Form 10-K on April 23, 2025.
- Regaining compliance has not impacted BKYI's listing or trading status on the Nasdaq Capital Market.
BIO-key International, Inc. (BKYI), a leader in Identity and Access Management (IAM) solutions, has successfully regained compliance with Nasdaq's listing requirements after a brief period of non-compliance. The company initially received a notice from Nasdaq on April 17, 2025, due to a delay in filing its Annual Report on Form 10-K for the year ended December 31, 2024. This delay constituted a violation of Nasdaq Listing Rule 5250(c)(1), which mandates the timely filing of periodic financial reports with the Securities and Exchange Commission (SEC).
The non-compliance notification, however, did not have an immediate effect on the listing or trading of BIO-key's common stock on the Nasdaq Capital Market. To address the issue, BIO-key filed the necessary Form 10-K on April 23, 2025. Subsequently, on April 24, 2025, the company received confirmation from Nasdaq that it had restored compliance with the listing rule, effectively closing the matter.
Based in Holmdel, New Jersey, BIO-key revolutionizes authentication and cybersecurity with its biometric-centric IAM software, securing access for over forty million users globally. Their solutions include cloud-hosted and on-premise options, offering secure and convenient access management that fits diverse customer needs.
